Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02595892 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

70

Enrollment

NIH

Sponsor class

Conditions

Ovarian Serous Tumor
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions

DRUG: Berzosertib
DRUG: Gemcitabine
DRUG: Gemcitabine Hydrochloride

Sponsor

National Cancer Institute (NCI)